NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Pharma POOL Roy Dunbar Mike Heim Dr. John Lechleiter Gerhard Mayr Dr. Lorenzo Tallarigo Senior Management Movements at Lilly Roy Dunbar, previously chief information officer of Eli Lilly, Indianapolis, has been appointed president of intercontinental operations, responsible for Asia, Africa, Middle East, Mexico, Brazil, and Andean/Central America. Mr. Dunbar joined Lilly in 1990. He has held positions in sales, sales management, marketing, and general management, including regional business unit manager, United Kingdom; general manager, Venezuela; and director, new product planning. Mike Heim, previously chief technology officer, has been promoted to chief information officer, succeeding Mr. Dunbar. Mr. Heim joined Lilly as a systems analyst. His assignments have included positions in information technology supporting nearly every aspect of the company’s business from R&D to manufacturing to sales and marketing. As chief technology officer since 2002, he was responsible for the implementation of the company’s overall technology strategy. In other company news, the pharmaceutical product and corporate development organization, responsible for developing and registering Lilly’s products, and the pharmaceutical operations organization, responsible for sales and marketing globally, are being consolidated. The new organization will be led by John Lechleiter, Ph.D., who is currently executive VP of pharmaceutical products and corporate development. Dr. Lechleiter becomes executive VP of pharmaceutical operations, following the retirement of Gerhard Mayr, executive VP of pharmaceutical operations, who is leaving March 1, 2004. Dr. Lechleiter joined Lilly in 1979 as a senior organic chemist in process research and development. Over the past 24 years, he has held numerous positions, including director of pharmaceutical product development; director, projects management; executive director of pharmaceutical product development for Lilly Research Laboratories; VP of regulatory affairs; and VP of development and regulatory affairs. Dr. Lechleiter became senior VP of pharmaceutical products in 1998 and assumed additional responsibilities, including business development and corporate strategy, in 2001 when he was named executive VP of pharmaceutical products and corporate development. Lorenzo Tallarigo, M.D., has been promoted to president, international operations, to lead all international affiliates. He had been president of intercontinental operations since 1999. Dr. Tallarigo joined Lilly in 1985 as a clinical research physician in Italy. He subsequently held positions as associate medical director and clinical research director before moving to the United States as director of pharmaceutical products management. He returned to Italy in 1993 as marketing director and had a number of other leadership assignments, including general manager, Italy, and general manager, France. Dick Van duyne Sankyo Creates Position for Worldwide Business Development Sankyo, a pharmaceutical company with headquarters in Tokyo, has named Dick Van Duyne head of global business development and executive VP of Sankyo Pharma, based in Parsippany, N.J. In these newly created roles, Mr. Van Duyne is responsible for worldwide business development, and he works directly with Takashi Shoda, president of Sankyo. He also is responsible for assisting the U.S. organization with external growth opportunity expansion. Mr. Van Duyne is based at the U.S. subsidiary’s Parsippany headquarters. Before joining Sankyo, Mr. Van Duyne was senior VP of business development at Pharmacia until its merger with Pfizer. He held a previous position as VP of corporate development and licensing at Warner-Lambert. While at Warner-Lambert, Mr. Van Duyne was instrumental in the creation of the Sankyo Parke Davis joint venture, the predecessor organization to Sankyo’s U.S. subsidiary. Mr. Van Duyne holds a bachelor of science degree from the University of Pennsylvania, a MBA from the Wharton School, and a law degree from Stanford University. Dr. Anton Hoos Altus Creates VP of Pharmaceutical Development Position Altus Biologics, a privately held pharmaceutical company that uses its proprietary and innovative protein crystallization technology to enable the rapid commercialization of high-value orally delivered protein-based products, has appointed Anton Hoos, M.D., to the newly created position of VP of pharmaceutical development, overseeing Altus’ product development activities. His responsibilities include project management, clinical R&D, regulatory affairs, quality assurance and control, process development, and manufacturing. Before joining Altus, Dr. Hoos had been with Aventis Behring and its predecessor companies for 13 years. While at Aventis Behring, he led multiple product-development and life-cycle management efforts, which resulted in product approvals with the FDA, EMEA, and the Japanese MHLW. Dr. Hoos received a M.D. from the University of Munich and a MBA from the University of Toronto. Tom Metcalfe Roche Appoints Head of Biomarker Program Roche has named Tom Metcalfe as head of the newly created Roche Biomarker Program (RBP). Roche, Basel, Switzerland, is one of the world’s leading research-oriented healthcare companies. The Roche Biomarker Program evolved from the company’s joint program in applied genomics (JPAG), a strategic initiative designed to identify and maximize synergies in the area of genomics within the pharmaceutical and diagnostic divisions in key disease areas. The RBP, however, encompasses a broader vision including proteomic, metabolic, and genomic approaches to biomarkers in support of all therapeutic areas being pursued by Roche. In this new capacity, Mr. Metcalfe is responsible for ensuring that the company maximizes potential synergies between pharmaceuticals and diagnostics and works on behalf of both divisions. He coordinates the projects and cross-functional work groups that contributed to the JPAG. Mr. Metcalfe previously was responsible for business development and operational excellence within Roche Molecular Diagnostics (RMD). His role in business development will transition to Greg Heath, head of clinical genomics at RMD. Mr. Metcalfe continues to be based within the diagnostics division in Pleasanton, Calif. Biotech POOL William Allender Mark E. Cline Cytomedix Announces Top Level Additions to the Management Team William Allender has joined Cytomedix as chief financial officer and Mark E. Cline has joined as president. Cytomedix, Little Rock, Ark., is a biotechnology company specializing in processes and products derived from autologous platelet releasates. Mr. Allender, 53, has more than 30 years of business, financial, and operational experience. Past services include director of audit at Michigan General. Mr. Allender has owned and operated his own Dallas-based CPA firm and, most recently, was senior operations analyst for Selkirk, a manufacturer of HVAC-related products. Mr. Allender received a BBA from Southern Methodist University, a MBA from Southern Methodist, and has been a licensed CPA since 1987. Mr. Cline, 52, joins Cytomedix with a wealth of entrepreneurial experience in developing and executing business strategies for early-stage public and private ventures. Mr. Cline has owned and operated successful businesses in the fields of medical devices, medical technology, restaurant management, oil and gas, film production, and human resources. Mr. Cline graduated from Memphis State University in 1975 with a B.S. degree in microbiology and parisitology. Mr. Cline also joins the board of directors. David Beier Pete Teeley Amgen Names Senior VP, Global Government Affairs David Beier has been named senior VP of global government affairs at Amgen, a biotechnology company located in Thousand Oaks, Calif. Mr. Beier is responsible for the operations of Amgen’s Washington, D.C., office and the management of corporate regulatory and legislative issues. Mr. Beier joins Amgen from the law firm of Hogan and Hartson in Washington, D.C., where he was a partner representing clients in the healthcare and technology fields, including pharmaceutical and biotechnology firms. He has an extensive government affairs and public policy background, and previously he served as chief domestic policy advisor to the VP of the United States from 1998 to early 2001. He also held positions as VP of government affairs and public policy for Genentech and staff counsel in the U.S. House of Representatives. Mr. Beier holds a J.D. from Albany Law School and a bachelor’s degree from Colgate University. Mr. Beier replaces Pete Teeley, who is assuming a new role as government affairs advisor for Amgen. Mr. Teeley also has an extensive government affairs background and founded Amgen’s Washington, D.C., office. Before joining Amgen, he held a variety of public positions in the 1980s, including serving as U.S. Ambassador to Canada and as press secretary and assistant to the VP of the United States. David Davidovic diaDexus names VP, Marketing and Sales David Davidovic joins diaDexus, a privately held biotechnology company located in South San Francisco, Calif., as VP of marketing and sales. Most recently, he was executive director of marketing at Merck, where he spent most of his career in a wide variety of positions. At diaDexus, his responsibilities include commercialization of the PLACtest, a blood test used to aid in the prediction of coronary heart disease. Mr. Davidovic brings more than 23 years of pharmaceutical experience to diaDexus, with extensive expertise in cardiology and urology marketing. He holds a B.S. in physiology and a MBA in marketing/information systems, both from McGill University in Montreal. Dr. Jonathan Smith AlphaVax Names Chief Scientific Officer AlphaVax has promoted Jonathan Smith, Ph.D., to the position of chief scientific officer. AlphaVax, Research Triangle Park, N.C., is a biotechnology company developing an innovative vaccine technology, called the ArV system. Dr. Smith is one of the original scientific founders of AlphaVax and has served as senior VP of discovery since 2000. He now is responsible for discovery, research, and development. Before joining AlphaVax, Dr. Smith was one of the leading scientists and vaccinologists at the U.S. Army Medical Research Institute of Infectious Diseases, where he served as chief of the department of viral biology. Dr. Smith graduated from Colby College and earned his Ph.D. in microbiology and virology from the University of Texas at Austin. He completed postdoctoral training at the Institute of Genetics in Cologne, Germany. Biopharmaceutical POOL Dr. Karen Auditore- Hargreaves Jack L. BOWMAN NeoRx Names President NeoRx, a cancer therapeutics development company, has appointed Karen Auditore-Hargreaves, Ph.D., as president. Dr. Hargreaves also continues to serve as chief operating officer, a position she has held since June 2003. Jack L. Bowman, who previously served as president, continues to serve as chairman and CEO. Dr. Auditore-Hargreaves, 51, joined Seattle-based NeoRx as VP of research and development in May 1999 and became senior VP of research and development in September 2001. In this capacity, she was responsible for clinical and manufacturing operations as well as R&D. Before joining NeoRx, she was VP of research at CellPro. Dr. Auditore-Hargreaves holds a Ph.D. in genetics from the University of California, Davis, and received her postdoctoral training at the Massachusetts Institute of Technology Center for Cancer Research. Dr. Glenn R. Larsen Hydra Biosciences Appoints Executive to Lead Research and Development Hydra Biosciences, a biopharmaceutical company pioneering the discovery of molecular regeneration medicines, has appointed Glenn R. Larsen, Ph.D., as chief scientific officer, executive VP of research and development. Dr. Larsen also becomes a member of Hydra’s board of directors. He joins the Cambridge, Mass.-based company from Wyeth Pharmaceuticals, where he served as VP of musculoskeletal sciences, directing R&D for Wyeth’s second largest therapeutic area in the fields of arthritis, inflammation, and tissue regeneration. Dr. Larsen also cochaired the musculoskeletal therapeutic area, responsible for directing Wyeth’s global commercial and development efforts for Enbrel, an anti-TNF agent for rheumatoid arthritis; Synvisc for osteoarthritis; and BMP-2, a bone regenerating factor. He began his career with Genetics Institute, where he held a variety of leadership positions in drug discovery, program management, and drug development, ultimately serving as VP of preclinical research and development. He received his Ph.D. in biochemistry from the State University of New York at Stony Brook and is a graduate of Harvard University’s Business School PMD program. William Pursley Xechem Names President and Chief Operating Officer Xechem International, New Brunswick, N.J., a fully integrated biopharmaceutical company focusing on proprietary technologies for orphan diseases, has named William Pursley, president and chief operating officer. He has served in executive positions at Genentech, Genzyme, Bio-Technology General, and Transkaryotic Therapies, where he established more than $1 billion in orphan disease markets. Dr. Edward B. Rubenstein MGI Pharma Names Senior VP, Medical and Commercial Development MGI Pharma, an oncology-focused biopharmaceutical company located in Bloomington, Minn., has appointed Edward B. Rubenstein, M.D., senior VP of medical and commercial development. Dr. Rubenstein most recently served as chief, section of medical supportive care, division of cancer medicine, department of palliative care and rehabilitation medicine at the University of Texas M.D. Anderson Cancer Care Center. He also is a professor of internal medicine at The University of Texas Medical School at Houston and professor of management and policy sciences at The University of Texas School of Public Health. Dr. Rubenstein brings to MGI Pharma experience and knowledge about cancer therapy and cancer supportive care, including chemotherapy-induced nausea and vomiting, mucositis, and febrile neutropenia. He is widely recognized as a thought leader in the field of cancer supportive care, has authored numerous scientific papers, and has frequently presented at international scientific meetings. Dr. Rubenstein received his medical degree from Hahnemann Medical College. Specialty POOL James Bruno Darren W. Buchwald Advancis Pharmaceutical Strengthens Senior-Management Team Advancis Pharmaceutical, which focuses on developing and commercializing novel anti-infective products, has added two key executives to lead the development of its sales and marketing capabilities. Pharmaceutical sales and marketing veteran James Bruno has joined Advancis as VP of sales and Darren W. Buchwald has joined the company as VP of pharmaceutical marketing. Mr. Bruno and Mr. Buchwald bring more than 25 years of pharmaceutical expertise to Advancis, Germantown, Md., where they are focused on building Advancis’ sales and marketing infrastructure in preparation for the commercialization of Advancis’ portfolio of anti-infective products. Mr. Bruno served as VP of international marketing at MedImmune, where he was responsible for coordinating the international launch of a monoclonal antibody and managing MedImmune’s distribution partners. He also served as marketing director of infectious disease products at Pharmacia and SmithKline Beecham. Before joining Advancis, Mr. Buchwald played a pivotal role in establishing strategic marketing at Human Genome Sciences and held senior marketing positions with Parexel International, Blue Cross Blue Shield, and Forest Laboratories. Dr. Brian M. Gallagher Colin W. Stewart CollaGenex Pharmaceuticals Appoints President and CEO CollaGenex Pharmaceuticals has appointed Colin W. Stewart to succeed Brian M. Gallagher, Ph.D., as the company’s president and CEO. CollaGenex, Newtown, Pa., is a specialty pharmaceutical company focused on providing innovative medical therapies to the dental and dermatology markets. Mr. Stewart also becomes a member of the CollaGenex board of directors. Dr. Gallagher remains on the board as a director and will provide certain consulting services to the company for a period of 24 months. Mr. Stewart, a 28-year veteran of the pharmaceutical industry, most recently was president and CEO of Muro Pharmaceutical, a subsidiary of Viatris. He previously spent 10 years with the ASTA Medica Group where he managed several pharmaceutical business units in increasingly senior management positions. He began his career as a sales representative for Winthrop Laboratories in the United Kingdom and subsequently held a number of positions of increasing responsibility with Winthrop in sales, marketing, and operational management. Mr. Stewart received a diploma in management studies from Teesside Polytechnic and a master of science degree in management studies from Durham University Business School. Dr. Christopher O’Brien Prestwick Pharmaceuticals Appoints Chief Medical Officer Prestwick Pharmaceuticals, a CNS specialty pharmaceutical company based in Washington, D.C., has appointed Christopher O’Brien, M.D., to the position of chief medical officer. Dr. O’Brien, a board certified neurologist and fellow of the American Academy of Neurology, has been a leader in clinical research with experimental therapeutics for more than 15 years. Before joining Prestwick, Dr. O’Brien was senior VP of global medical affairs at Elan Pharmaceuticals. He served on both the commercial and R&D management teams and oversaw Phase IIIb and IV trials along with the medical science-liaison team and the medical information service. For the preceding 10 years, he was VP of the Colorado Neurological Institute and medical director of the Huntington’s Disease and Parkinson’s Disease Centers of Excellence in Colorado. Currently an adjunct professor in the Neuroscience Department at University of California San Diego, he has held faculty appointments at the University of Colorado Health Sciences Center and at the University of Rochester School of Medicine. Dr. O’Brien received his M.D. and neurology training at the University of Minnesota and fellowship training in movement disorders and neuropharmacology at the University of Rochester. He has served as investigator or director for more than 100 clinical trials and is credited with more than 75 publications in the neuroscience literature. Dr. O’Brien has served as board member with various national foundations supporting Huntington’s disease, Parkinson’s disease, dystonia, and Tourette’s syndrome. Genomics POOL Donald B. Hawthorne Ardais Appoints President and CEO Ardais, a clinical genomics company that provides products and services for drug discovery, has appointed Donald B. Hawthorne president and CEO, and member of the company’s board of directors. Mr. Hawthorne has held leadership positions in the healthcare industry for more than 20 years and has extensive experience in growing emerging companies. He replaces Gregory D. Phelps, who left Ardais, Lexington, Mass., to pursue other opportunities. Since 1999, Mr. Hawthorne has been a contract operating partner to the healthcare venture capital community, providing general management and strategic advisory services. Formerly, he was a partner and chief financial officer at Ampersand Ventures, a private equity firm. Mr. Hawthorne holds a MBA from the Stanford Graduate School of Business. Emerging POOL Dr. Andre G. Pernet Quark Biotech Appoints President Quark Biotech has appointed Andre G. Pernet, Ph.D., as president. Quark Biotech, Fremont, Calif., is a privately held company that is pioneering endpoint-driven drug development. Dr. Pernet is currently chairman of CURx Pharma and serves on the board of directors of Kaleidos Pharmaceuticals. In recent years, he also served on the boards of Celeris, Synsorb, Advanced Pharma, and Genescape, and on the scientific board of Pathogenesis. Dr. Pernet previously served as chairman and CEO of Genset, a European genomics company. He began his career at Abbott Laboratories in 1973 as a research chemist and over the next 25 years held positions of increasing responsibility. He received his Maitrise es science and License es science from the Université de Montpellier, France, and degree of chemical engineer from Ecole Nationale Supérieure de Chimie de Montpellier. Dr. Pernet also received a diploma in business management from McGill University and a Ph.D. in chemistry from the University of Montreal. Daniel Swisher Dr. James Young Sunesis Appoints CEO and Executive Chairman Sunesis Pharmaceuticals has appointed Daniel Swisher as CEO and James Young, Ph.D., as executive chairman. Sunesis, South San Francisco, Calif., is an emerging, research-and-development-based pharmaceutical company that applies fragment-based drug discovery to create superior therapeutics for challenging and important disease targets. Mr. Swisher also has been appointed to the Sunesis board of directors. He brings more than 15 years of experience in pharmaceutical product development, commercialization, and finance, most recently serving as chief operating officer of Sunesis. He joined the company in January 2002 as chief business officer and chief financial officer. Before joining Sunesis, he was senior VP of sales and marketing for Alza. Mr. Swisher earned a B.A. degree from Yale University and a MBA from the Stanford Graduate School of Business. Dr. Young joined Sunesis in April 2000 as the company’s CEO. Previously, he held senior management positions at Alza, Affymax, Sepracor, and Zoecon. Dr. Young earned a B.S. from Fordham University and a Ph.D. from Cornell University. CRO POOL Dr. Edward G. Spack SRI International Names Senior Director SRI International, an independent research and technology development organization based in Menlo Park, Calif., has named Edward G. “Ted” Spack, Ph.D., as a senior director in its biosciences division. In this role, Dr. Spack coordinates PharmaSTART, a collaboration of world-leading research organizations that have joined forces to translate unrealized drug research investments into potentially lifesaving drugs. The PharmaSTART consortium’s founding members are Stanford University; the University of California, San Diego; the University of California, San Francisco; and the UCSF campus of the California Institute for Quantitative Biomedical Research (QB3). The University of California, Berkeley, also recently joined the consortium. Through PharmaSTART, SRI offers drug-development and consultation services, including guidance on government funding opportunities, to the consortium members’ primary investigators. In addition to his PharmaSTART role, Dr. Spack is focused on growing SRI’s business in developing biological medicines, especially vaccines and antibody therapies to control biothreat agents and infectious diseases such as HIV and SARS. Most recently, Dr. Spack was senior director of applied research for InterMune, a biopharmaceutical company focused on the development of drug therapies for pulmonary and infectious diseases and cancer. Dr. Spack has participated in the design and implementation of 10 clinical trials, holds one patent and has two patents pending, is an advisory member of several medical societies, has authored more than 30 publications, and has been an invited speaker at dozens of presentations. He received a postdoctoral fellowship in immunology from Stanford University, a Ph.D. in cell biology from Johns Hopkins University, and a B.S. from Muhlenberg College. Service POOL Stephan Benzekri Penelope L. Mace Dr. Wayne T. Smith Neil Wasserstein V2 GfK Expands Marketing Research Team V2 GfK, a global pharmaceutical marketing research and consulting company located in Blue Bell, Pa., has appointed four senior research professionals. The staff additions are in response to the firm’s increased global project activity through its affiliation with the GfK Group. Stephan Benzekri, formerly a research manager at Market Measures/Cozint, has joined V2 GfK as a project manager of advanced analytics. Mr. Benzekri’s experience includes the management of research studies, covering a wide range of methodologies and therapeutic classes. Mr. Benzekri’s research experience includes work as both an operations project manager as well as a research manager. Before Market Measures/Cozint, Mr. Benzekri worked with P S L Consulting, where he developed and then managed the firm’s online research capabilities. Penelope L. Mace also has been appointed senior consultant. She joins V2 GfK from NFO Healthcare, where as a project manager, she was responsible for handling the global research needs for many of the firm’s clients. Ms. Mace’s diverse healthcare experience, before working with NFO Healthcare, includes marketing research positions at KPR and MOI. She is trained as a registered nurse and has held a number of clinical and supervisory positions. Wayne T. Smith, Ph.D., formerly a VP at Roper ASW, has joined V2 GfK as a senior consultant, bringing more than 15 years of marketing research experience in both qualitative and quantitative methodologies. Dr. Smith has taught graduate-level statistics and experimental design and applied these lessons to market research in the form of positioning, pricing, and modeling. He previously held positions at BAI/Global, Chilton, and the Gallup Organization. Dr. Smith holds a Ph.D. in clinical psychology from the University of Connecticut. Neil Wasserstein has joined V2 GfK as senior consultant from Vox Medica, bringing with him more than 30 years of primary marketing research experience in the healthcare and pharmaceutical industries, as well as consumer packaged goods. Mr. Wasserstein brings to V2 GfK significant expertise in quantitative research approaches, including the measuring of brand equity/health, concept testing, advertising copy testing, pricing and market share potential, customer satisfaction, and segmentation studies. In addition, he has moderated hundreds of focus groups for clients in many industries at Arbor, AC Nielsen, and ABC Television. Dr. Brad Davidson MBS/Vox Adds to Management Team MBS/Vox, a research-based consultancy unit specializing in the analysis of physician-patient communication in actual in-office visits, has appointed Brad Davidson, Ph.D., as account director. MBS/Vox, Wayne, N.J., is a unit of CommonHealth, a WPP Group company. Included in his responsibilities are the analysis and presentation of findings for much of the unit’s ongoing collection of physician-patient communications. Previously, Dr. Davidson was employed as a principal research associate with Lexicon Branding, a naming and brand-identity consultancy. He received his master and doctorate degrees from Stanford University Department of Linguistics. Dr. Alex Derchak Cardiopulmonary Physiologist Enhances VivoMetrics’ Clinical Research Department Alex Derchak, Ph.D., has been named director of clinical research at VivoMetrics, a privately held company that provides continuous ambulatory monitoring products and services for the collection, analysis, and reporting of subject-specific physiologic data. In this new position, he helps develop protocols for the use of the company’s LifeShirt, a noninvasive, continuous ambulatory monitoring system, in clinical trials with a wide range of endpoints in various disease states. Before joining Ventura, Calif.-based VivoMetrics, Dr. Derchak was a senior scientific communications associate in global scientific information and communications at Eli Lilly. He was responsible for coordinating the analysis and communication of clinical data related to a first-in-class, lifesaving molecule. In addition, he employed his research background in cardiopulmonary physiology, leading writing teams in the analysis and communication of clinical and preclinical trial data. Dr. Derchak earned his premedical bachelor of science degree from the University of Notre Dame; his masters of science in exercise physiology from the School of Health, Physical Education, and Recreation at Indiana University; and his doctorate in human performance/exercise physiology from the School of Graduate Studies at Indiana University. Theresa M. Liddy Dolge Stephanie L. Tofani Dorland Global Health Communications Adds to Public Relations Staff Dorland Public Relations, a division of Dorland Global Health Communications, Philadelphia, has added two members to its staff. Theresa M. Liddy Dolge has joined Dorland Public Relations as a senior account executive, concentrating on account activities for Cephalon. She brings to Dorland media expertise in a wide range of health categories, most recently serving in the healthcare group of Fleishman-Hillard. Ms. Dolge also is experienced in educational campaigns and has worked with the International Foundation for Functional Gastrointestinal Disorders and the Epilepsy Foundation of New Jersey. Stephanie L. Tofani has joined Dorland Public Relations as an account coordinator. She services accounts on behalf of multiple clients, including Eisai/Janssen and Merck. Henry Hill Fast Track Hires Veteran to Lead Global Customer Care and Professional Services Team Fast Track Systems, Fort Washington, Pa., a clinical development optimization company, has named Henry Hill as VP of enterprise and professional services. Mr. Hill is responsible for Fast Track’s global customer-care group and the newly formed professional services team. Mr. Hill has more than 20 years of experience in worldwide software development and professional services. Most recently, he was chief operating officer at Liquent, where he was responsible for more than doubling the worldwide growth of the professional services division. He also has held senior management positions with TCG Software Services, Accenture, and Sea-Land Service Susquehanna University. He has a MBA from Fairleigh Dickenson University. Eric John Dr. Melinda Shorr TVG Promotes Key Marketing Research Staff TVG Marketing Research & Consulting has promoted Eric John and Melinda Shorr, Ph.D., to the positions of associate VP. TVG, a PDI company located in Fort Washington, Pa., employs marketing research methodologies to help companies generate strategic marketing options, develop sustainable competitive advantages, and determine investment decisions. Mr. John formerly held the position of executive director. As a member of TVG’s advanced quantitative research team, Mr. John has provided analytic expertise in the areas of both physician and consumer research. He also is a member of the TVG seminar series faculty. Before joining TVG in 2001, Mr. John was director of marketing research and planning at Novo Nordisk Pharmaceuticals. Dr. Shorr is a member of TVG’s qualitative research team and has participated in the launch of a number of industry blockbusters. In her new role as associate VP, she is responsible for advancing TVG’s depth of methodological and therapeutic expertise. Dr. Shorr holds a Ph.D. in counseling psychology from the University of Pennsylvania. Kathy Laudani Business Development Rep Added to MMS Staff Medical Marketing Service (MMS), a Woodale, Ill.-based healthcare list manager and the original AMA database licensee, has added Kathy Laudani to its staff as a business development representative. Ms. Laudani is responsible for working with medical publishers, ad agencies, and other clients to provide MMS lists and services, including controlled circulation management for medical publications, mailing lists, and MMS’ Med-E-Mail Physician Broadcast E-mail Service. Ms Laudani has had extensive pharmaceutical marketing experience as Abelson-Taylor group media director, president of KL Media Services, and as a CME project manager for Abbott, Lilly, GlaxoSmithKline, Bristol-Myers Squibb, and Merck. David Pendleton CHS Welcomes New Member to Marketing Professionals Team CHS, an inChord company and a provider of pharmaceutical and biotech contract marketing services, has added David Pendleton to its team of marketing professionals. He is responsible for providing a broad range of marketing solutions and best-practice insights to clients. He joins CHS, Scottsdale, Ariz., from North American Scientific, a medical-device and biopharmaceutical company, where he was the director of marketing and clinical operations. Mr. Pendleton holds a bachelor’s degree in biology, magna cum laude, from Northeastern University. Medical-Education POOL Linnéa Elliott Adrienne Fitzgerald-Hirt The Curry Rockefeller Group Adds to Staff Linnéa Elliott has been named VP, editorial director, at The Curry Rockefeller Group, Tarrytown, N.Y. Curry Rockefeller is a group of companies dedicated to thought-leader focused medical education. Ms. Elliott has held editorial management and other senior positions in the past at Global Edge, Avenue E – Health Strategies, The Cortlandt Group, Scientific American, and Hospital Practice. In related company news, AAF-MED, the independent ACCME-accredited subsidiary of Curry Rockefeller Group, has named Adrienne Fitzgerald-Hirt director of funded projects. Ms. Hirt has more than five years of experience in the field of medical education, most recently serving as account director for MPE Communications. Before that, she spent five years with Pfizer as a medical sales representative and as a central nervous system healthcare representative. Ms. Hirt was a summa cum laude graduate of the State University of New York at Plattsburg with a bachelor of science degree in business marketing. Anne Jacobson Christine E. Matsko Columbia MedCom Names Medical Writer and Account Manager Anne Jacobson, MPH, has been named a medical writer at Columbia MedCom Group, which comprises two wholly owned subsidiaries INNOVIA Education Institute and Medicalliance. Ms. Jacobson is responsible for researching, writing, and editing a variety of medical-education materials, serving as liaison with authors and speakers, assisting speakers with preparation for events, and assuring scientific integrity in writing projects. Previously, Ms. Jacobson was a freelancer who wrote, edited, and coordinated the production of continuing medical-education materials and promotional publications with faculty members and guest authors. A Duke University graduate, Ms. Jacobson, earned her masters of public health at Emory University School of Public Health. Christine E. Matsko has joined the Columbia, Md.-based company as account manager. She is responsible for managing, monitoring, and ensuring the quality and consistency of client programming for her direct accounts. In this role, she is a liaison with the client and with her team to oversee the progress of projects through every stage of implementation. Previously, Ms. Matsko was an account manager for Trahan, Burden & Charles Advertising & Public Relations. Ms. Matsko is a Mount Saint Mary’s College graduate. Dr. George Mammen Phoenix Marketing Solutions Hires VP, Strategic Planning and Development George Mammen, Ph.D., former chief operating officer of Australia’s Prince of Wales Medical Research Institute, has joined Phoenix Marketing Solutions in the newly created position of VP, strategic planning and development. Phoenix is a medical-education company in Warren, N.J. In this newly created post, he specializes in tailoring programs for pharmaceutical clients. Dr. Mammen brings to Phoenix an extensive background in brand-management and medical-education strategies. While at the Prince of Wales Institute, he arranged research agreements and oversaw patent portfolios and licensing, marketing, and fundraising. Before that, he launched Discovery Australia, the medical-education division of Medicus Group International in Sydney, where he was general manager and VP. A Ph.D. graduate in pharmacology from Monash University in Melbourne, Dr. Mammen also has a MBA from Deakin University in Melbourne. He is a member of the Australian Biotech Association, the Young Australian Professionals in America, and the Licensing Executives Society of USA and Canada. Consulting POOL Dr. Tim Kearns Rosa Pharmaceuticals Names Leader of Market Analysis Practice Rosa Pharmaceuticals, a leader in drug-development risk management, has named Tim Kearns, Ph.D., as a managing director and head of Rosa’s market-analysis practice. Located in Cupertino, Calif., Rosa Pharmaceuticals provides strategic risk-management and drug-development services to pharmaceutical and biotechnology firms. Dr. Kearns specializes in computer modeling and simulation of complex markets and has more than 20 years of experience in market modeling. He has conducted a wide range of market planning and strategy projects for new and existing products and services in the pharmaceutical and medical-device industries. Before joining Rosa, Dr. Kearns was principal and corporate manager at Applied Decision Analysis/PricewaterhouseCoopers, where he led the development of new methods to model complex marketplace behavior, notably in the healthcare, consumer products, and telecom and computer industries. He is currently an associate professor and chair of the computer science department at California Polytechnic State University. He holds a Ph.D. and M.Sc. in mathematics from the University of Notre Dame and a B.A. in mathematics from Boston College. Dr. Cecilia Lenk Decision Resources Fills VP, Information Technology, Position Decision Resources, a research and advisory company focused on pharmaceutical and healthcare issues, has promoted Cecilia Lenk, Ph.D., to VP of information technology. During the past three years, Dr. Lenk has developed and led Decision Resources’ technology strategy, which is key to the company’s near- and long-term business success. In collaboration with other departments throughout the company, she has launched a new Website, a content-management system, a client-contact system, new product digital platforms, a new intranet, and customer portals. Before joining Decision Resources, Waltham, Mass., in 2001, Dr. Lenk was president of Webivore Knowledge Systems. She has developed numerous national and international Internet initiatives in the areas of science, health, and science education for business clients and leading organizations, including the National Science Foundation and the National Institutes of Health. Dr. Lenk holds a Ph.D. in biology from Harvard University and a B.S. in engineering from The Whiting School of Engineering at The Johns Hopkins University. Dave P. Miller Ovation Research Group Names Director, Statistical Analysis Dave P. Miller has been named director of statistical analysis at Ovation Research Group, a global health economics and outcomes research and consulting firm located in Highland Park, Ill. In this position, he collaborates with clients and clinicians to develop and implement statistical analysis plans that meet both strategic and scientific research objectives. He also leads Ovation’s statistical analysis team in conducting analyses and communicating results through published manuscripts and presentations. Mr. Miller has more than 15 years experience as a statistician and outcomes researcher. He is author or coauthor of more than 40 peer-reviewed articles appearing in such publications as The New England Journal of Medicine, JAMA, and Circulation, and has served as an associate editor of The American Statistician. He also has presented papers at the national meetings of the American Statistical Association and the International Biometric Society. Previously, Mr. Miller was director of biostatistics for R2 Technology, as well as VP of data management and analysis for Quintiles’ late-phase unit in San Francisco. Technology/Web POOL Dr. Elizabeth Patterson The Conectics Group Hires Information Services Manager The Conectics Group has added Elizabeth Patterson, M.L.I.S., Ph.D., to the staff as information services manager. The Conectics Group, Parsippany, N.J., is the digital development, research, and media-planning services unit of CommonHealth, a leading healthcare-communications resource and a WPP Group company. She is responsible for CommonHealth’s reference library, providing research support for CommonHealth companies and assisting with various digital information services. Dr. Patterson previously was employed as the government documents assistant in the reference department of Drew University’s library. Ashesh Shah Software Veteran to Lead Saband Technologies Ashesh Shah has been named president of Saband Technologies, a subsidiary of Cadient. Saband develops innovative technologies to streamline pharmaceutical branding and optimize the commercial potential of drug discoveries and launches. Previously, Mr. Shah had been cofounder of InterMedia Interactive Solutions, a provider of Internet technology solutions for the pharmaceutical industry. In September 2003, Cadient, located in Conshohocken, Pa., acquired key pharmaceutical technology assets from InterMedia, along with offshore software development capabilities. These assets now form the basis of Saband. Mr. Shah, who has worked with many leading pharmaceutical companies, is well-known within the industry for integrating technologies into state-of-the-art marketing programs that embrace a range of new media, including the Internet. In addition to leading Saband Technologies, Mr. Shah supports the expansion of Saband Software Technologies Private Ltd., a growing offshore research and development facility. He is a graduate of the management and technology program at the University of Pennsylvania. He also holds degrees in computer science from the Moore School of Engineering and in strategic management/corporate finance from the Wharton School of Business. Agency POOL Joe Cupani LLKFB Fills Executive VP, Chief Creative Officer Position New York-based LLKFB, a full-service direct-marketing communication agency and Omnicom Group company, has named Joe Cupani executive VP and chief creative officer. Mr. Cupani was most recently executive VP and chief creative officer at Wunderman. He succeeds Carmine “Sonny” Farese, executive VP, executive creative director, and one of the founding partners of LLKFB, who retired at the end of last year. In this new role, Mr. Cupani works closely with Bob Lieber, chairman and CEO of LLKFB, and Loreen Babcock, the agency’s president. He is responsible for the creative product of the entire agency. During the course of his 25-year career, Mr. Cupani has worked on a broad range of products and services, such as AT&T, American Express, Sony, Roche Pharmaceuticals, Amtrak, the U.S. Army, and Jaguar. Please send your personnel announcements to email@example.com. talent pool executive appointments and promotions in the healthcare industry